» Articles » PMID: 25483783

ANKHD1 Represses P21 (WAF1/CIP1) Promoter and Promotes Multiple Myeloma Cell Growth

Overview
Journal Eur J Cancer
Specialty Oncology
Date 2014 Dec 9
PMID 25483783
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

ANKHD1 (Ankyrin repeat and KH domain-containing protein 1) is highly expressed and plays an important role in the proliferation and cell cycle progression of multiple myeloma (MM) cells. ANKHD1 downregulation modulates cell cycle gene expression and upregulates p21 irrespective of the TP53 mutational status of MM cell lines. The present study was aimed to investigate the role of ANKHD1 in MM in vitro clonogenicity and in vivo tumourigenicity, as well as the role of ANKHD1 in p21 transcriptional regulation. ANKHD1 silencing in MM cells resulted in significantly low no. of colonies formed and in slow migration as compared to control cells (p < 0.05). Furthermore, in xenograft MM mice models, tumour growth was visibly suppressed in mice injected with ANKHD1 silenced cells compared to the control group. There was a significant decrease in tumour volume (p = 0.006) as well as in weight (p = 0.02) in the group injected with silenced cells compared to those of the control group. Co-immunoprecipitation and chromatin immunoprecipitation (ChIP) assays confirmed the interaction between p21 and ANKHD1. Moreover, overexpression of ANKHD1 downregulated the activity of a p21 promoter in luciferase assays. Decrease in luciferase activity suggests a direct role of ANKHD1 in p21 transcriptional regulation. In addition confocal analysis after U266 cells were treated with Leptomycin B (LMB) for 24 h showed accumulation of ANKHD1 inside the nucleus as compared to untreated cells where ANKHD1 was found to be predominantly in cytoplasm. This suggests ANKHD1 might be shuttling between cytoplasm and nucleus. In conclusion, ANKHD1 promotes MM growth by repressing p21 a potent cell cycle regulator.

Citing Articles

Upregulating ANKHD1 in PS19 mice reduces Tau phosphorylation and mitigates Tau-toxicity-induced cognitive deficits.

Tian X, Le N, Zhao Y, Alawamleh D, Schwartz A, Meyer L bioRxiv. 2024; .

PMID: 39605390 PMC: 11601383. DOI: 10.1101/2024.11.15.623890.


Leveraging diverse cellular stress patterns for predicting clinical outcomes and therapeutic responses in patients with multiple myeloma.

Xu J, Dong X, Dong J, Peng Y, Xing M, Chen L J Cell Mol Med. 2024; 28(17):e70054.

PMID: 39245797 PMC: 11381192. DOI: 10.1111/jcmm.70054.


Evaluating the Molecular Properties and Function of ANKHD1, and Its Role in Cancer.

Mullenger J, Zeidler M, Fragiadaki M Int J Mol Sci. 2023; 24(16).

PMID: 37629022 PMC: 10454556. DOI: 10.3390/ijms241612834.


The feedback loop of ANKHD1/lncRNA MALAT1/YAP1 strengthens the radioresistance of CRC by activating YAP1/AKT signaling.

Yao P, Wu Y, Zhao K, Li Y, Cao J, Xing C Cell Death Dis. 2022; 13(2):103.

PMID: 35110552 PMC: 8810793. DOI: 10.1038/s41419-022-04554-w.


USP22-mediated deubiquitination of PTEN inhibits pancreatic cancer progression by inducing p21 expression.

Ren D, Sun Y, Li D, Wu H, Jin X Mol Oncol. 2021; 16(5):1200-1217.

PMID: 34743406 PMC: 8895442. DOI: 10.1002/1878-0261.13137.